Your session is about to expire
← Back to Search
Modified Virus Therapy for Cancer
Study Summary
This trial is testing a modified virus that may be able to kill cancer cells, with or without a drug that may stop tumor cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 2 trial • 124 Patients • NCT01334918Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any ongoing infections, tuberculosis, or hepatitis.I am willing and able to undergo treatment aimed at curing my disease.I have a condition that affects my blood's ability to clot.I am 18 years old or older.I have recently undergone other treatments.I do not have heart conditions, active brain disorders, HIV, or a weak immune system.My PTCL has returned after standard treatment failed.My blood cancer can be measured by tests.My multiple myeloma has returned or didn't respond to treatment with IMID, a proteasome inhibitor, and an alkylating agent.I can take care of myself and am up and about more than half of my waking hours.I have B-cell lymphoma (not Burkitt's) or HCN at any stage.My brain and spinal cord are free from cancer.
- Group 1: Group B (VSV-IFNbeta-NIS, ruxolitinib, cyclophosphamide)
- Group 2: Group C (VSV-IFNbeta-NIS, ruxolitinib, nivolumab)
- Group 3: Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab)
- Group 4: Group A (VSV-IFNbeta-NIS)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being accepted as participants in this research study?
"Correct. The clinicaltrials.gov website highlights that this experiment, which was initially advertised on April 4th 2017, is currently recruiting participants. 65 individuals need to be enrolled from two distinct research facilities."
Is this clinical exploration actively seeking participants?
"Confirming the details from clinicaltrials.gov, this study is still open for enrolment. The trial was first made available on April 4th 2017 and its most recent update was on February 3rd 2022."
Has the Pharmacological Study been given regulatory authorization by the FDA?
"Our team's assessment of Pharmacological Study's safety is a score of 1 since it is currently in Phase 1 and there has only been limited clinical data on efficacy and security."
For what medical ailments is Pharmacological Study regularly administered?
"Pharmacological Study can be deployed to address clouded lenses, senile cataracts, and abscesses."
Have past pharmacological studies yielded any noteworthy outcomes?
"The initial Pharmacological Study was conducted in 1997 at the City of Hope Comprehensive Cancer Center, and since then there have been 1785 successful studies. Currently, 912 active trials are taking place across America--particularly in Rochester, Minnesota."
Share this study with friends
Copy Link
Messenger